Article info
PDFLetter
Antiangiogenic activity of the selective cyclooxygenase 2 inhibitor rofecoxib in human colorectal cancer liver metastases
- Correspondence to:
Professor M A Hull
Molecular Gastroenterology, Leeds Institute of Molecular Medicine, University of Leeds, St James’s University Hospital, Leeds LS9 7TF, UK; M.A.Hull{at}leeds.ac.uk
Citation
Antiangiogenic activity of the selective cyclooxygenase 2 inhibitor rofecoxib in human colorectal cancer liver metastases
Publication history
- First published June 9, 2006.
Online issue publication
April 18, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2006 by Gut